期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 6, 页码 1289-1301出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1869966
关键词
Chronic lymphocytic leukemia; biomarker; prognosis; therapy; prediction
资金
- Mayo Clinic K2R Career Development Program
Chronic lymphocytic leukemia (CLL) is characterized by marked heterogeneity, with advancements in disease biology driving the era of targeted therapy and improving risk stratification methods; important tests and biomarkers during leukemia treatment can help enhance the quality of patient care and treatment prognosis.
Chronic lymphocytic leukemia (CLL) is a mature B-cell malignancy characterized by marked heterogeneity. Discoveries in disease biology over the past two decades have helped explain clinical variability and heralded the arrival of the targeted therapy era. In this article, we review improvements in risk stratification which have coincided with this progress, including individual biomarkers and their incorporation into prognostic models. Amidst an ever-expanding list of biomarkers, we seek to bring focus to the essential tests to improve patient care and counseling at particular times in the disease course, beginning with prognosis at diagnosis. The majority of patients do not require treatment at the time of diagnosis, making time-to-first-treatment a key initial prognostic concern. Prognostic and predictive biomarkers are then considered at subsequent major junctures, including at the time of treatment initiation, while on therapy, and at the time of relapse on novel agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据